Arbutus Biopharma (NASDAQ:ABUS) is set to announce its earnings results after the market closes on Monday, March 19th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
Shares of Arbutus Biopharma (NASDAQ ABUS) opened at $5.80 on Monday. The firm has a market capitalization of $319.30, a P/E ratio of -1.16 and a beta of 1.02. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03. Arbutus Biopharma has a 52-week low of $2.55 and a 52-week high of $8.25.
An institutional investor recently raised its position in Arbutus Biopharma stock. Vanguard Group Inc. lifted its stake in Arbutus Biopharma Corp (NASDAQ:ABUS) by 2.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 77,413 shares of the biopharmaceutical company’s stock after buying an additional 2,035 shares during the period. Vanguard Group Inc. owned about 0.14% of Arbutus Biopharma worth $279,000 at the end of the most recent reporting period. 62.14% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on Monday” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.themarketsdaily.com/2018/03/12/arbutus-biopharma-abus-set-to-announce-quarterly-earnings-on-monday.html.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.